نتایج جستجو برای: cisplatin toxicity

تعداد نتایج: 143067  

Journal: :Japanese Journal of Pharmacology 1986

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2006
C Boni F Zanelli M Ambroggi A Bologna

Cisplatin-based chemotherapy remains the backbone in the treatment of non-small-cell lung cancer (NSCLC), with significantly improved survival and better quality of life [1]. Platinum based doublets, with new drugs like Gemcitabine, Vinorelbine and Taxanes, are superior to single agent chemotherapy and should be preferred in first line treatment of patients with advanced NSCLC, according to cur...

Journal: :Biomedical and Pharmacology Journal 2019

Journal: :Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2012
Qingwen Hu Donna D Zhang Limei Wang Hongxiang Lou Dongmei Ren

Eriodictyol-7-O-glucoside, a flavonoid isolated from Dracocephalum rupestre, is among the most potent free radical scavenger. In the present study, we identified eriodictyol-7-O-glucoside as a novel nuclear factor E2-related factor 2 (Nrf2) activator using a high-throughput cellular screening method. This compound activated Nrf2 signaling pathway and was able to stabilize Nrf2 by delaying Nrf2 ...

Journal: :Inorganic chemistry 2006
Diane Bouvet Alain Michalowicz Sylvie Crauste-Manciet Denis Brossard Karine Provost

Platinum compounds constitute a discrete class of DNA-damaging anticancer drug agents, including cisplatin, carboplatin, and oxaliplatin. The toxicity of such drugs raises the problem of waste detoxification. Diethyl dithiocarbamate (DDTC) is recommended by the World Heath Organization (WHO) for the destruction of cisplatin, but the degradation product has not been structurally characterized. T...

Journal: :Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 1992
A Sasaki M Ohtani N Miyanaga H Zhongtao H Akaza K Koiso R Noguchi R Takanashi

The antitumor effect of tumor necrosis factor (TNF) in combination with Cis-diammine-dichloroplatinum (II) (Cisplatin) upon implanted bladder carcinoma (MBT-2) in mice was analysed together with the toxicity. Mice were implanted into the bladder wall with about 10(4) cells MBT-2 viable cells. TNF was the purified human natural tumor necrosis factor. The antitumor effects were evaluated by the v...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2013
M Kreuter J Vansteenkiste J R Fischer W Eberhardt H Zabeck J Kollmeier M Serke N Frickhofen M Reck W Engel-Riedel S Neumann M Thomeer C Schumann P De Leyn T Graeter G Stamatis I Zuna F Griesinger M Thomas

BACKGROUND Adjuvant chemotherapy is beneficial in non-small-cell lung cancer (NSCLC). However, balancing toxicity and efficacy mandates improvement. PATIENTS AND METHODS Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 m...

Journal: :Toxicology and applied pharmacology 2007
Aya Hirose Eri Sato Hajime Fujii Buxiang Sun Hiroshi Nishioka Okezie I Aruoma

Cisplatin (cis-diaminedichloroplatinum (II) or CDDP) (a widely used platinum-containing anticancer drug) is nephrotoxic and has a low percentage of tolerance in patients during chemotherapy. The active hexose correlated compound (AHCC) is an extract of Basidiomycotina marketed as a supplement for cancer patients due to its nutrients and fibre content and its ability to strengthen and optimize t...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2003
C Balaña J-L Manzano I Moreno B Cirauqui A Abad A Font J-L Mate R Rosell

BACKGROUND The aim of this phase II study was to determine toxicity, response rate, time to progression, and overall survival of cisplatin, etoposide and gemcitabine in patients with carcinoma of unknown primary tumour site. PATIENTS AND METHODS Thirty patients with no previous chemotherapy and not belonging to a treatable group were treated with cisplatin 70 mg/m(2) on day 1, etoposide 70 mg...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003
Nicholas J Vogelzang James J Rusthoven James Symanowski Claude Denham E Kaukel Pierre Ruffie Ulrich Gatzemeier Michael Boyer Salih Emri Christian Manegold Clet Niyikiza Paolo Paoletti

PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone. PATIENTS AND METHODS Chemotherapy-naive patient...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید